(RTTNews) - While reporting financial results for the fourth quarter on Thursday, Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2025.

Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth. The company also issued full ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results tomorrow before the bell. Here’s what you need to know. Bristol-Myers Squibb beat analysts’ revenue ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in its home state of New Jersey. BMS’ latest workforce reduction affects ...

ELECTRA (KFDX/KJTL) — Police in Electra are working to track down those responsible for a string of vandalism incidents across the city. Officers were called to the city park Sunday afternoon ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Bristol Myers Squibb (BMY) reports results for the quarter ended December 2024. While this widely-known consensus ...

Ratings for Bristol-Myers Squibb BMY were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table encapsulates their recent ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of $39.00. Terence Flynn’s rating is based on ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

In recent trading, shares of Bristol Myers Squibb Co. (Symbol: BMY) have crossed above the average analyst 12-month target price of $59.62, changing hands for $59.67/share. When a stock reaches ...